Two Middle East respiratory syndrome vaccines: first step for other coronavirus vaccines
Journal Article - Open Access
INTERNATIONAL VACCINE INST SEOUL (KOREA) SEOUL
Pagination or Media Count:
Since the outbreak of severe acute respiratory syndrome coronavirus SARS-CoV in 2002, the emergence and expansion of endemic and epidemic corona viruses has been accelerating on a scale not seen for any other group of viruses with pandemic potential. In the past two decades alone, five new human coronaviruses have been discovered, three of which are highly pathogenic. The coronavirus disease 2019 COVID-19 pandemic is just the latest example of the danger posed by zoonotic diseases, foreshadowed by the regional, but unabated, emergence of Middle East respiratory syndrome coronavirus MERS-CoV. In recognition of its intrinsic threat to public health and as a prototypical member of the family Coronaviridae, WHO, in 2015, prioritised MERS-CoV as a pathogen to which increased resources should be dedicated for countermeasure research and development. The newly established Coalition for Epidemic Preparedness Innovations followed suit with investments in the development of candidate MERS-CoV vaccines. In subsequent years, three vaccine candidates have completed initial clinical evaluation and are now ready for advanced testing.
- Medicine and Medical Research